Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial

[1]  Gudrun Schleiermacher,et al.  Advances in Risk Classification and Treatment Strategies for Neuroblastoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T. Matsushige,et al.  A nationwide survey of opsoclonus–myoclonus syndrome in Japanese children , 2015, Brain and Development.

[3]  S. O'Neil,et al.  Effect of Increased Immunosuppression on Developmental Outcome of Opsoclonus Myoclonus Syndrome (OMS) , 2015, Journal of child neurology.

[4]  D. Bansal,et al.  Clinical Profile and Outcome of Children With Opsoclonus-Myoclonus Syndrome , 2014, Journal of child neurology.

[5]  R. Ransohoff,et al.  BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy , 2013, Journal of Neuroinflammation.

[6]  M. Pranzatelli,et al.  Ofatumumab for a rituximab‐allergic child with chronic‐relapsing paraneoplastic opsoclonus–myoclonus , 2012, Pediatric blood & cancer.

[7]  A. Look,et al.  Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. , 2010, The New England journal of medicine.

[8]  H. Brisse,et al.  Opsoclonus-myoclonus in children associated or not with neuroblastoma. , 2010, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[9]  B. Lang,et al.  A prospective study of the presentation and management of dancing eye syndrome/opsoclonus-myoclonus syndrome in the United Kingdom. , 2010, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[10]  C. Catsman-Berrevoets,et al.  Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long‐term follow‐up , 2009, Pediatric blood & cancer.

[11]  S. Parodi,et al.  Long-Term Follow-Up of Neuroblastoma-Associated Opsoclonus-Myoclonus-Ataxia Syndrome , 2009, Neuropediatrics.

[12]  V. Pistoia,et al.  Immunological mechanisms in opsoclonus-myoclonus associated neuroblastoma. , 2009, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[13]  Barbara Hero,et al.  The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Pranzatelli,et al.  Rituximab (anti-CD20) Adjunctive Therapy for Opsoclonus-Myoclonus Syndrome , 2006, Journal of pediatric hematology/oncology.

[15]  K. Preissner,et al.  Functional characterisation of autoantibodies from patients with pediatric opsoclonus–myoclonus-syndrome , 2005, Journal of Neuroimmunology.

[16]  B. Hero,et al.  Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. , 2005, Cancer letters.

[17]  K. Preissner,et al.  Surface‐binding autoantibodies to cerebellar neurons in opsoclonus syndrome , 2005, Annals of neurology.

[18]  S. Verhulst,et al.  B- and T-cell markers in opsoclonus–myoclonus syndrome: Immunophenotyping of CSF lymphocytes , 2004, Neurology.

[19]  M. Rosenfeld,et al.  Autoantigen diversity in the opsoclonus‐myoclonus syndrome , 2003, Annals of neurology.

[20]  Hiroyuki Shimada,et al.  Terminology and morphologic criteria of neuroblastic tumors , 1999, Cancer.

[21]  P. Breitfeld,et al.  High dose cyclophosphamide with carboplatin: a tolerable regimen suitable for dose intensification in children with solid tumors. , 1997, Journal of pediatric hematology/oncology.

[22]  S. Cohn,et al.  Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. , 1997, Medical and pediatric oncology.

[23]  V. Colamaria,et al.  Treatment with intravenously administered immunoglobulins of the neuroblastoma-associated opsoclonus-myoclonus. , 1996, The Journal of pediatrics.

[24]  P. D. de Alarcon,et al.  Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G. , 1995, The Journal of pediatrics.

[25]  S. Davis,et al.  The incidence and epidemiologic characteristics of neuroblastoma in the United States. , 1987, American journal of epidemiology.

[26]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[27]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[28]  R. Arceci.  Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641 , 2012 .

[29]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[30]  J. Posner.  Autoantibodies in childhood opsoclonus-myoclonus syndrome. , 1997, Jornal de Pediatria.